[go: up one dir, main page]

AU1578295A - Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders - Google Patents

Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders

Info

Publication number
AU1578295A
AU1578295A AU15782/95A AU1578295A AU1578295A AU 1578295 A AU1578295 A AU 1578295A AU 15782/95 A AU15782/95 A AU 15782/95A AU 1578295 A AU1578295 A AU 1578295A AU 1578295 A AU1578295 A AU 1578295A
Authority
AU
Australia
Prior art keywords
arylcyclobutylalkylamines
seizures
treatment
neurological disorders
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15782/95A
Inventor
William Roger Buckett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co PLC filed Critical Boots Co PLC
Publication of AU1578295A publication Critical patent/AU1578295A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU15782/95A 1994-02-11 1995-02-09 Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders Abandoned AU1578295A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9402641A GB9402641D0 (en) 1994-02-11 1994-02-11 Therapeutic agents
GB9402641 1994-02-11
PCT/EP1995/000440 WO1995021615A1 (en) 1994-02-11 1995-02-09 Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders

Publications (1)

Publication Number Publication Date
AU1578295A true AU1578295A (en) 1995-08-29

Family

ID=10750231

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15782/95A Abandoned AU1578295A (en) 1994-02-11 1995-02-09 Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders

Country Status (5)

Country Link
AU (1) AU1578295A (en)
GB (1) GB9402641D0 (en)
IL (1) IL112602A0 (en)
WO (1) WO1995021615A1 (en)
ZA (1) ZA951088B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6288125B1 (en) * 2000-03-17 2001-09-11 Knoll Pharmaceuticals Company Treatment of hiatial hernia
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
KR100830002B1 (en) 2005-01-06 2008-05-15 씨제이제일제당 (주) Inorganic Acid Salts of Sibutramine
KR20060080818A (en) 2005-01-06 2006-07-11 씨제이 주식회사 Sulfonates of sibutramine
KR20060080817A (en) 2005-01-06 2006-07-11 씨제이 주식회사 Dicarboxylate of Sibutramine
CN102786444A (en) * 2012-07-24 2012-11-21 上海瑞博化学有限公司 Preparation method for sulfonates of sibutramine analogues

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526656A (en) * 1967-05-25 1970-09-01 Parke Davis & Co (1-arylcyclobutyl)carbonyl carbamic acid derivatives
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine.

Also Published As

Publication number Publication date
IL112602A0 (en) 1995-12-08
ZA951088B (en) 1996-01-23
WO1995021615A1 (en) 1995-08-17
GB9402641D0 (en) 1994-04-06

Similar Documents

Publication Publication Date Title
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AU4585996A (en) Pyrazolopyrimidines for treatment of neuronal and other disorders
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AUPM672594A0 (en) A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
PL339425A1 (en) Treatment of behavioural disorders
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AUPO274596A0 (en) Method for the treatment of neurological or neuropsychiatric disorders
AU2972497A (en) Treatment of oils
AU2058697A (en) Treatment of sleep disorders
AU4131296A (en) Treatment of disorders with duloxetine
AU3151097A (en) Pharmaceutical for treating of neurological and neuropsychiatric disorders
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
AUPM456894A0 (en) Treatment for gastric disorders
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
GB9419048D0 (en) Treatment of muscular disorders
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
AU4486797A (en) Compositions and methods useful for the treatment of neurological and mental disorders
AU2245695A (en) Composition for treating neurological disorders
AUPO504297A0 (en) Treatment of neurological disorders
GB9413556D0 (en) The treatment of neurological and psychiatric disorders
AU7622898A (en) The use of oxandrolone in the treatment of a neurological disorder